Orchestra BioMed宣布CEO将出席H.C. Wainwright第28届全球投资大会并做演讲

这是一份例行的投资者会议参与公告，仅宣布CEO将于三周后出席H.C. Wainwright年会并做演讲。公告未包含任何新的临床数据、监管进展、合作更新或财务指引，不构成可交易的催化剂。市场不会对此类例行公告做出价格反应。

📄 原文GlobeNewswire All Public Companies↗ 原文

Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or t…

不做 Orchestra BioMed（OBIO.US）

例行投资者会议参与公告，不含任何增量信息（无新临床数据、无监管进展、无合作更新、无财务指引），不构成可交易催化剂。会议本身在三周后（9月16日），届时若有实质披露将作为新事件另行研判。

展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

Orchestra BioMed发布GlobeNewswire通稿，宣布CEO将于2026年9月16日出席H.C. Wainwright第28届全球投资大会做演讲及投资者一对一会面。这是上市公司最常见的例行沟通之一，不披露任何增量事实（无新数据、无新合作、无监管进展、无指引变化），不改变任何市场参与者对公司价值的预期，历史上此类公告不引发股价反应。结论：不构成可交易事件。

🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 low ↗

先例如何影响了这次决策

对本次决策的影响:先例不影响结论；此类事件本身不构成催化剂

方向:会议参与公告类事件历史上不引发显著价格反应，无需先例验证

涨幅量级:不适用——此类公告无价格反应可测量

形态:不适用

工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0

search_processed_events 成功 stock_tools HTTP · 1,380 ms
{"result": "search_processed_events:agent query=`david hochman conference 2026 | obio h.c. wainwright investment conference | orchestra biomed conference presentation`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.3/72 小时、11338 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}

原文全文

展开原文 · 2,600 字

NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C. Wainwright 28
th
Annual Global Investment Conference on Wednesday, Sept. 16, 2026 at 9:00am ET, and will also host one-on-one meetings with investors that day.
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit
www.orchestrabiomed.com
, and follow us on
LinkedIn
.
Investor Contact:
Silas Newcomb
Orchestra BioMed
snewcomb@orchestrabiomed.com
Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。